← All indications
Waldenstrom Macroglobulinemia
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
Drugs by status
Approved for this indication (2)
Phase 3 trials (12)
Phase 2 trials (88)
- simvastatin
- methylprednisolone
- ibritumomab tiuxetan
- acalabrutinib
- allogeneic natural killer cells
- antineoplaston a10
- venetoclax
- bendamustine
- bi-1206
- brentuximab vedotin
- busulfan
- lenalidomide
- temsirolimus
- Iopofosine
- nelarabine
- ct-1530
- doxycycline
- prednisone
- selinexor
- doxorubicin
- enzastaurin
- n-(4-hydroxyphenyl)all-trans retinamide
- folic acid
- obinutuzumab
- gemcitabine
- oblimersen sodium
- tacrolimus
- naltrexone
- cyanocobalamin
- idelalisib
- +58 more
Phase 1 trials (66)
- di-leu16-il2
- fau
- alvespimycin
- Mavorixafor
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- avn-944
- sorafenib
- belinostat
- cb-839
- spebrutinib
- cdx-301
- devimistat
- di-b4
- entinostat
- genetically engineered lymphocyte therapy
- paclitaxel
- imatinib
- ar-42
- aldesleukin
- in111 anti-cd45 monoclonal antibody bc8
- ispinesib
- ly3214996
- methoxyamine
- morab-004
- buparlisib
- sunitinib
- rifaximin
- ro4929097
- sapanisertib
- bevacizumab
- +36 more
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (21)
- Amgen
- BeOne Medicines
- Taunton and Somerset NHS Foundation Trust
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of London
- University of Washington
- French Innovative Leukemia Organisation
- French Study Group on Chronic Lymphoid Leukemia
- Polish Lymphoma Research Group
- University of Kiel
- University of Leeds
- University of Athens
- University of Ulm
- University of Amsterdam
- Karolinska Institute
- The University of Hong Kong
- Centre Hospitalier Schaffner France
- Portuguese Institute of Oncology
- The Lymphoma Study Association
- Johnson and Johnson
Organization Involved with Phase 2 Indications (117)
- AbbVie
- Spectrum Pharmaceuticals
- Human Genome Sciences
- Aceragen, Inc/
- Seattle Genetics
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Onyx
- Roche
- Gilead Sciences
- Immunomedics
- AstraZeneca
- Merck
- Eli Lilly
- Genentech
- Genzyme
- AEterna Zentaris
- Novartis
- Bayer
- Centaurus Biopharma Co., Ltd.
- GlaxoSmithKline
- LifeTime Pharmaceuticals
- Sunesis Pharmaceuticals
- TG Therapeutics, Inc.
- University of Roma La Sapienza
- University of Pennsylvania
- Academic and Community Cancer Research United
- Rockefeller University
- University of Arizona
- +87 more
Organization Involved with Phase 1 Indications (30)
- ADC Therapeutics SARL
- Takeda
- Vertex
- Morphotek
- Arno Therapeutics
- ArQule
- Ascentage Pharma Group Inc.
- Bio-Path Holdings, Inc.
- X4 Pharmaceuticals
- University of Pittsburgh
- Brown University
- Cancer and Leukemia Group B (CALGB)
- Dartmouth University
- Johns Hopkins University
- Rhode Island Hospital
- Wake Forest University
- University of California, Davis
- University of California, San Francisco
- University of Colorado, Denver
- University of Ulsan
- Calithera Biosciences
- Boryung Pharmaceutical Company
- City of Hope National Medical Center
- University of Wisconsin
- The Leukemia and Lymphoma Society
- Sungkyunkwan University
- OHSU Knight Cancer Institute
- Memorial Sloan-Kettering Cancer Center
- Shanghai YingLi Pharmaceutical Co. Ltd.
- VelosBio
Organization Involved with Other Experimental Indications (1)